[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2024000505A - Variantes de virus adenoasociados y metodos para usarlos. - Google Patents

Variantes de virus adenoasociados y metodos para usarlos.

Info

Publication number
MX2024000505A
MX2024000505A MX2024000505A MX2024000505A MX2024000505A MX 2024000505 A MX2024000505 A MX 2024000505A MX 2024000505 A MX2024000505 A MX 2024000505A MX 2024000505 A MX2024000505 A MX 2024000505A MX 2024000505 A MX2024000505 A MX 2024000505A
Authority
MX
Mexico
Prior art keywords
methods
associated viruses
variant adeno
adeno
variant
Prior art date
Application number
MX2024000505A
Other languages
English (en)
Inventor
David Schaffer
Joshua Dudman
Adam Hantman
Loren Looger
Kimberly Ritola
Dougal Gowanlock Robinson Tervo
Sarada Viswanathan
Alla Karpova
Bum-Yeol Hwang
Original Assignee
Hughes Howard Med Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hughes Howard Med Inst filed Critical Hughes Howard Med Inst
Publication of MX2024000505A publication Critical patent/MX2024000505A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/015—Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6027—Vectors comprising as targeting moiety peptide derived from defined protein from viruses ssDNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

La presente divulgación provee variantes de AAV que exhiben preferencia por el movimiento retrógrado en las neuronas y métodos de uso de dichas variantes.
MX2024000505A 2016-06-15 2018-12-14 Variantes de virus adenoasociados y metodos para usarlos. MX2024000505A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662350361P 2016-06-15 2016-06-15
US201662404585P 2016-10-05 2016-10-05

Publications (1)

Publication Number Publication Date
MX2024000505A true MX2024000505A (es) 2024-03-19

Family

ID=59258370

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018015770A MX2018015770A (es) 2016-06-15 2017-06-15 Variantes de virus adenoasociados y metodos para usarlos.
MX2024000505A MX2024000505A (es) 2016-06-15 2018-12-14 Variantes de virus adenoasociados y metodos para usarlos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018015770A MX2018015770A (es) 2016-06-15 2017-06-15 Variantes de virus adenoasociados y metodos para usarlos.

Country Status (27)

Country Link
US (2) US10961282B2 (es)
EP (2) EP4268852A3 (es)
JP (2) JP7094277B2 (es)
KR (2) KR20230054754A (es)
CN (2) CN116003532A (es)
AU (2) AU2017286652B2 (es)
BR (1) BR112018076090A2 (es)
CA (1) CA3028113A1 (es)
DK (1) DK3472183T5 (es)
EA (1) EA201990033A1 (es)
ES (1) ES2962611T3 (es)
FI (1) FI3472183T3 (es)
HR (1) HRP20231403T1 (es)
HU (1) HUE063755T2 (es)
IL (2) IL263719B2 (es)
LT (1) LT3472183T (es)
MA (1) MA44546B1 (es)
MX (2) MX2018015770A (es)
MY (1) MY190221A (es)
PH (1) PH12018502664A1 (es)
PL (1) PL3472183T3 (es)
PT (1) PT3472183T (es)
RS (1) RS64769B1 (es)
SG (1) SG11201811189RA (es)
SI (1) SI3472183T1 (es)
WO (1) WO2017218842A1 (es)
ZA (1) ZA201900278B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014194132A1 (en) 2013-05-31 2014-12-04 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
KR102234930B1 (ko) 2016-05-13 2021-04-02 4디 몰레큘러 테라퓨틱스 아이엔씨. 아데노-관련 바이러스 변이체 캡시드 및 그 용도
MA44546B1 (fr) 2016-06-15 2021-03-31 Univ California Virus adéno-associés variants et procédés d'utilisation
CA3029833A1 (en) 2016-07-29 2018-02-01 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
AU2018324477A1 (en) 2017-08-28 2019-10-17 The Regents Of The University Of California Adeno-associated virus capsid variants and methods of use thereof
CA3078277A1 (en) * 2017-10-16 2019-04-25 Vigeneron Gmbh Aav vectors
SG11202101042SA (en) * 2018-07-31 2021-02-25 Univ Cornell Gene therapy methods to control organ function
AU2019346447A1 (en) 2018-09-26 2021-04-29 California Institute Of Technology Adeno-associated virus compositions for targeted gene therapy
WO2021022208A1 (en) * 2019-08-01 2021-02-04 Kaplitt Michael G Targeted gene therapy to treat neurological diseases
US20230265453A1 (en) * 2020-07-08 2023-08-24 Baylor College Of Medicine Gene therapy for stxbp1 encephalopathy
CN111825772B (zh) * 2020-07-30 2023-10-20 中国科学院精密测量科学与技术创新研究院 具有变异衣壳蛋白的腺相关病毒及其应用
JP2023536080A (ja) 2020-08-06 2023-08-23 ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダ 遺伝子治療によるアルツハイマー病などのタウオパチーの治療に使用するためのウイルス粒子
US20240059743A1 (en) * 2020-12-16 2024-02-22 Chidren's Medical Research Institute Aav capsids and vectors
AU2021401998A1 (en) * 2020-12-16 2023-08-03 Children's Medical Research Institute Adeno-associated virus capsids and vectors
JP2024523891A (ja) 2021-06-17 2024-07-02 メイラグティーエックス ユーケー アイアイ リミティド Ａａｖ産生方法
IL310018A (en) 2021-07-14 2024-03-01 Meiragtx Uk Ii Ltd KCNV2 gene therapy
WO2023288184A2 (en) * 2021-07-14 2023-01-19 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for treating chronic pain and for retrograde transduction of neurons
AU2022310166A1 (en) 2021-07-14 2024-02-29 Meiragtx Uk Ii Limited Retgc gene therapy
WO2023131811A2 (en) 2021-12-15 2023-07-13 Meiragtx Uk Ii Limited Polycistronic expression of gut peptides
WO2023192450A1 (en) * 2022-03-30 2023-10-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Adeno-associated virus vectors for nucleic acid delivery to retinal ganglion cells and/or retinal pigment epithelium cells
WO2024059667A2 (en) * 2022-09-13 2024-03-21 Dyno Therapeutics, Inc. Capsid variants and methods of using the same
WO2024056902A2 (en) 2022-09-16 2024-03-21 Christopher Shaw Compositions and methods for treating neurological diseases
WO2024079662A1 (en) 2022-10-11 2024-04-18 Meiragtx Uk Ii Limited Upf1 expression constructs
WO2024079661A1 (en) 2022-10-11 2024-04-18 Meiragtx Uk Ii Limited Atp7b gene therapy
WO2024079657A1 (en) 2022-10-11 2024-04-18 Meiragtx Uk Ii Limited Formulations for aav gene therapy
WO2024079655A1 (en) 2022-10-11 2024-04-18 Meiragtx Uk Ii Limited Chromatography methods for purification of aav capsids
WO2024079665A1 (en) 2022-10-11 2024-04-18 Meiragtx Uk Ii Limited Nucleic acid regulatory elements for constitutive gene expression and methods of use
WO2024126696A1 (en) 2022-12-14 2024-06-20 King's College London Compositions and methods for treating neurological diseases
WO2024148179A2 (en) * 2023-01-05 2024-07-11 Emugen Therapeutics Llc Retro-aav and use in treating neurodegenerative diseases
WO2024148189A2 (en) * 2023-01-05 2024-07-11 Emugen Therapeutics Llc Neuronal promoters and uses thereof
WO2024161022A2 (en) 2023-02-03 2024-08-08 King's College London Compositions and methods for treating neurological diseases
WO2024213660A1 (en) 2023-04-13 2024-10-17 Meiragtx Uk Ii Limited Inflammation-inducible promoters

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US9233131B2 (en) * 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
WO2006119150A2 (en) * 2005-04-29 2006-11-09 Beth Israel Deaconess Medical Center Compositions and methods for targeting of viral vectors
US20090215879A1 (en) 2008-02-26 2009-08-27 University Of North Carolina At Chapel Hill Methods and compositions for adeno-associated virus (aav) with hi loop mutations
WO2010093784A2 (en) 2009-02-11 2010-08-19 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
EP3254703B1 (en) * 2011-04-22 2020-02-19 The Regents of The University of California Adeno-associated virus virions with variant capsid and methods of use thereof
US9719992B2 (en) 2011-10-07 2017-08-01 Howard Hughes Medical Institute Genetically encoded biosensors
WO2013174760A1 (en) 2012-05-25 2013-11-28 Deutsches Krebsforschungszentrum Optimized aav-vectors for high transduction rates in dendritic cells
US9518980B2 (en) 2012-10-10 2016-12-13 Howard Hughes Medical Institute Genetically encoded calcium indicators
US9518996B2 (en) 2013-08-05 2016-12-13 Howard Hughes Medical Institute Fluorescent protein-based calcium integrators
US9585971B2 (en) * 2013-09-13 2017-03-07 California Institute Of Technology Recombinant AAV capsid protein
CN104592364B (zh) * 2013-10-30 2018-05-01 北京大学 定点突变和定点修饰的腺相关病毒、其制备方法及应用
GB201403684D0 (en) * 2014-03-03 2014-04-16 King S College London Vector
WO2015164757A1 (en) * 2014-04-25 2015-10-29 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
WO2016054554A1 (en) 2014-10-03 2016-04-07 University Of Massachusetts Heterologous targeting peptide grafted aavs
BR112017010447A2 (pt) * 2014-11-21 2018-05-15 The University Of North Carolina At Chapel Hill vetores de aav direcionados ao sistema nervoso central
US9644007B2 (en) 2014-12-23 2017-05-09 Howard Hughes Medical Institute Red genetically encoded calcium indicators and methods of use
KR102234930B1 (ko) 2016-05-13 2021-04-02 4디 몰레큘러 테라퓨틱스 아이엔씨. 아데노-관련 바이러스 변이체 캡시드 및 그 용도
MA44546B1 (fr) 2016-06-15 2021-03-31 Univ California Virus adéno-associés variants et procédés d'utilisation
CA3029833A1 (en) * 2016-07-29 2018-02-01 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof

Also Published As

Publication number Publication date
PT3472183T (pt) 2023-11-16
JP2019518793A (ja) 2019-07-04
FI3472183T3 (fi) 2023-11-03
RS64769B1 (sr) 2023-11-30
CN109641939B (zh) 2022-11-08
DK3472183T5 (da) 2024-09-09
AU2017286652A1 (en) 2019-01-24
EP4268852A2 (en) 2023-11-01
BR112018076090A2 (pt) 2019-03-26
AU2021225247A1 (en) 2021-09-30
JP2022126759A (ja) 2022-08-30
CN116003532A (zh) 2023-04-25
IL263719B1 (en) 2023-05-01
LT3472183T (lt) 2023-09-25
MA44546A1 (fr) 2019-07-31
AU2021225247B2 (en) 2023-02-16
ES2962611T3 (es) 2024-03-20
AU2017286652B2 (en) 2021-10-07
EP4268852A3 (en) 2024-02-07
WO2017218842A1 (en) 2017-12-21
IL300981A (en) 2023-04-01
HUE063755T2 (hu) 2024-01-28
KR20230054754A (ko) 2023-04-25
IL263719A (en) 2019-01-31
SG11201811189RA (en) 2019-01-30
IL263719B2 (en) 2023-09-01
PH12018502664A1 (en) 2019-10-07
MA44546B1 (fr) 2021-03-31
SI3472183T1 (sl) 2023-11-30
PL3472183T3 (pl) 2024-02-12
US11939355B2 (en) 2024-03-26
JP7094277B2 (ja) 2022-07-01
EA201990033A1 (ru) 2019-06-28
KR20190039930A (ko) 2019-04-16
US10961282B2 (en) 2021-03-30
DK3472183T3 (da) 2023-11-06
JP7579301B2 (ja) 2024-11-07
MX2018015770A (es) 2019-08-29
MY190221A (en) 2022-04-06
HRP20231403T1 (hr) 2024-02-16
US20210230231A1 (en) 2021-07-29
EP3472183B1 (en) 2023-08-09
CN109641939A (zh) 2019-04-16
US20190300579A1 (en) 2019-10-03
CA3028113A1 (en) 2017-12-21
ZA201900278B (en) 2022-04-28
EP3472183A1 (en) 2019-04-24
KR102522661B1 (ko) 2023-04-18

Similar Documents

Publication Publication Date Title
PH12018502664A1 (en) Variant adeno-associated viruses and methods of using
MX2022001043A (es) Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas.
MX2024010175A (es) Moleculas de anticuerpo contra april y usos de las mismas.
PH12017500877B1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
MX2020002694A (es) Moleculas de anticuerpo que se unen a tim-3 y usos de las mismas.
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
EP4245376A3 (en) Antibody molecules to pd-l1 and uses thereof
SG10201804931QA (en) Anti-cll-1 antibodies and immunoconjugates
MY176855A (en) Anti-jagged1 antibodies and methods of use
MX2020003593A (es) Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos.
PH12017501990B1 (en) Imidazopyrazinones as pde1 inhibitors
MX2018008302A (es) Anticuerpo antigrupo de diferenciacion 9 (anti-cd9) terapeutico.
PH12017501864A1 (en) Compositions and methods for treating autism
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
MX2017006692A (es) Trastornos neurodegenerativos.
MX2016009597A (es) Terapias para el influenzavirus a subtipo h7n9.
MX2017002277A (es) Anticuerpos que potencian el factor h y sus usos.
MX2016010168A (es) Hexahidrofuropirroles como inhibidores de pde1.
EA201792492A1 (ru) Aml-антигены и их применение
AU367315S (en) Pool
TH1501006032A (th) อุปกรณ์ประมวลผลความสัมพันธ์เนื้อหาและสร้างเนื้อหาใหม่จากความสัมพันธ์
NZ744340A (en) Anti-jagged1 antibodies and methods of use
TH1601000218A (th) ระบบการชำระเงินที่ปลอดภัยทางอินเทอร์เน็ตและวิธีการชำระเงินที่ปลอดภัย